[1] Tatsumi Y, Nagashima M, Shibanushi T, et al. Mechanism of action of efinaconazole, a novel triazole antifungal agent[J]. Antimicrob Agents Chemother, 2013, 57(5):2405-2409.
[2] Patel T, Dhillon S. Efinaconazole:first global approval[J]. Drugs, 2013, 73(17):1977-1983.
[3] Gupta AK, Paquet M. Management of onychomycosis in Canada in 2014[J]. J Cutan Med Surg, 2015, 19(3):260-273.
[4] Jarratt M, Siu WJ, Yamakawa E, et al. Safety and pharmacokinetics of efinaconazole 10% solution in healthy volunteers and patients with severe onychomycosis[J]. J Drugs Dermatol, 2013, 12(9):1010-1016.
[5] Poulakos M, Grace Y, Machin JD, et al. Efinaconazole and tavaborole[J]. J Pharm Pract, 2017, 30(2):245-255.
[6] Zeichner JA,Stein Gold LS, Korotzer A. Penetration of (14C)-efinaconazole topical solution, 10%, does not appear to be influenced by nail polish[J]. J Clin Aesthet Dermatol, 2014, 7(9):34-36.
[7] Lipner SR, Scher RK. Efinaconazole in the treatment of onychomycosis[J]. Infect Drug Resist, 2015, 8:163-172.
[8] Glynn M, Jo W, Minowa K, et al. Efinaconazole:developmental and reproductive toxicity potential of a novel antifungal azole[J]. Reprod Toxicol, 2015, 52(4):18-25.
[9] Jo W, Glynn M, Nejishima H, et al. Nonclinical safety assessment of efinaconazole solution (10%) for onychomycosis treatment[J]. Regul Toxicol Pharmacol, 2014, 70(1):242-253.
[10] Gupta AK, Versteeg SG, Shear NH. Common drug-drug interactions in antifungal treatments for superficial fungal infections[J]. Expert Opin Drug Metab Toxicol, 2018,14(4):387-398.
[11] JoSiu WJJ, Tatsumi Y, Senda H, et al. Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis[J]. Antimicrob Agents Chemother, 2013, 57(4):1610-1616.
[12] Tschen EH, Bucko AD, Oizumi N, et al. Efinaconazole solution in the treatment of toenail onychomycosis:a phase 2, multicenter, randomized, double-blind study[J]. J Drugs Dermatol, 2013, 12(2):186-192.
[13] Rodriguez DA. Efinaconazole topical solution, 10%, for the treatment of mild and moderate toenail onychomycosis[J]. J Clin Aesthet Dermatol, 2015, 8(6):24-29.
[14] Tosti A, Elewski BE. Treatment of onychomycosis with efinaconazole 10% topical solution and quality of life[J]. J Clin Aesthet Dermatol, 2014, 7(11):25-30.
[15] Elewski BE, Rich P, Pollak R, et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis:two phase Ⅲ multicenter, randomized, double-blind studies[J]. J Am Acad Dermatol, 2013, 68(4):600-608.
[16] Markinson B, Caldwell B. Efinaconazole topical solution, 10% efficacy in patients with onychomycosis and coexisting tinea pedis[J]. J Am Podiatr Med Assoc, 2015, 105(5):407-411.
[17] Robbins JM. Treatment of onychomycosis in the diabetic patient population[J]. J Diabetes Complications, 2003, 17(2):98-104.
[18] Vlahovic TC, Joseph WS. Efinaconazole topical, 10% for the treatment of toenail onychomycosis in patients with diabetes[J]. J Drugs Dermatol, 2014, 13(10):1186-1190.
[19] Iwata A, Watanabe Y, Kumagai N, et al. In vitro and in vivo assessment of dermatophyte acquired resistance to efinaconazole, a novel triazole antifungal[J]. Antimicrob Agents Chemother, 2014, 58(8):4920-4922.
[20] Noguchi H, Hiruma M, Matsumoto T, et al. Ungual aspergillosis successfully treated with topical efinaconazole[J]. J Dermatol, 2017, 44(7):848-850.
[21] Tupaki-Sreepurna A, Jishnu BT, Thanneru V, et al. An assessment of in vitro antifungal activities of efinaconazole and itraconazole against common non-dermatophyte fungi causing onychomycosis[J]. J Fungi (Basel), 2017, 3(2):E20.
[22] Sugiura K, Sugimoto N, Hosaka S, et al. The low keratin affinity of efinaconazole contributes to its nail penetration and fungicidal activity in topical onychomycosis treatment[J]. Antimicrob Agents Chemother, 2014, 58(7):3837-3842.
[23] Hirohata A, Hanafusa T, Mabuchi-Kiyohara E, et al. Contact dermatitis caused by efinaconazole solution for treatment of onychomycosis[J]. Contact Dermatitis, 2015, 73(3):190-192.
[24] Oiso N, Tatebayashi M, Kawada A. Allergic contact dermatitis caused by efinaconazole:positive patch test reactions up to 0.1% pet[J]. Contact Dermatitis, 2017, 76(1):53-54.
[25] Yamaguchi Y, Hoshina D, Furuya K. Onychomadesis caused by efinaconazole[J]. Contact Dermatitis, 2017, 76(1):57-58.
[26] Del Rosso JQ, Reece B, Smith K, et al. Efinaconazole 10% solution:a new topical treatment for onychomycosis:contact sensitization and skin irritation potential[J]. J Clin Aesthet Dermatol, 2013, 6(3):20-24.